Folic acid-targeted disulfide-based cross-linking micelle for enhanced drug encapsulation stability and site-specific drug delivery against tumors

Abstract

Although the shortcomings of small molecular antitumor drugs were efficiently improved by being entrapped into nanosized vehicles, premature drug release and insufficient tumor targeting demand innovative approaches that boost the stability and tumor responsiveness of drug-loaded nanocarriers. Here, we show the use of the core cross-linking method to generate a micelle with enhanced drug encapsulation ability and sensitivity of drug release in tumor. This kind of micelle could increase curcumin (Cur) delivery to HeLa cells in vitro and improve tumor accumulation in vivo. We designed and synthesized the core cross-linked micelle (CCM) with polyethylene glycol and folic acid-polyethylene glycol as the hydrophilic units, pyridyldisulfide as the cross-linkable and hydrophobic unit, and disulfide bond as the cross-linker. CCM showed spherical shape with a diameter of 91.2 nm by the characterization of dynamic light scattering and transmission electron microscope. Attributed to the core cross-linking, drug-loaded CCM displayed higher Nile Red or Cur-encapsulated stability and better sensitivity to glutathione than noncross-linked micelle (NCM). Cellular uptake and in vitro antitumor studies proved the enhanced endocytosis and better cytotoxicity of CCM-Cur against HeLa cells, which had a high level of glutathione. Meanwhile, the folate receptor-mediated drug delivery (FA-CCM-Cur) further enhanced the endocytosis and cytotoxicity. Ex vivo imaging studies showed that CCM-Cur and FA-CCM-Cur possessed higher tumor accumulation until 24 hours after injection. Concretely, FA-CCM-Cur exhibited the highest tumor accumulation with 1.7-fold of noncross-linked micelle Cur and 2.8-fold of free Cur. By combining cross-linking of the core with active tumor targeting of FA, we demonstrated a new and effective way to design nanocarriers for enhanced drug encapsulation, smart tumor responsiveness, and elevated tumor accumulation.

Introduction

With the emergence and rapid development of nanocarriers for drug delivery systems in recent decades, the shortcomings of small molecule antitumor drugs, such as high side effects and low solubility, were efficiently improved. After being entrapped by various nanosized vehicles,^1–4 the circulation time of therapeutic agents was prolonged, and the concentration of drugs accumulated into tumor sites was enhanced owing to the enhanced permeability and retention effect.^5,6 However, the nanocarrier for this drug delivery system is still confronted with a series of barriers when applied to antitumor activities in vitro and in vivo.^7–9 Among them, encapsulation stability is an urgent problem to be solved. First, when drug-loaded nanocarriers are exposed to the blood stream or normal tissues, the core-shell structure of nanocarriers may be dissolved and diluted to a concentration below their critical micelle concentration (CMC), which can result in a trail of side effects.^10,11 Second, conventional nanocarriers that loaded drugs by physical entrapment suffered from the premature release of drugs in systemic circulation after being injected into humans or animals. That is, up to 20%–30% of the entrapped drugs are leaked out before being delivered to the therapeutic sites, which cause off-target effects.¹²

To address this issue, the cross-linked micelle (CM) was proposed. A shell cross-linked micelle (SCM) has been previously reported and was achieved via radical oligomerization of the pendent styrenyl groups on the coronal blocks in a tetrahydrofuran–water mixture.^13–15 Structure and drug encapsulation of the SCM were more stable than noncross-linked micelle (NCM) with respect to infinite dilution in the blood circulation. Nevertheless, the drugs loaded into the SCM could not quickly release in cells; it had to follow a passive diffusion because of the nonsensitive cores of the SCM.^16–19 Meanwhile, the SCM by the preparation of a diblock copolymer was obliged to consider the intermicellar cross-linking, which might lead to micelle aggregates. The large micelle aggregates can be cleared by the mononuclear phagocyte system. Therefore, a nanocarrier with characteristics of high encapsulation and controlled drug release is forcefully required so as to improve the therapeutic efficiency in the treatment of tumors.

In most cases, some core cross-linked micelles (CCMs) were designed by different intermolecular forces between polymer chains, such as Van der Waals forces, hydrogen bonds, and hydrophobic and electrostatic interactions.^20,21 However, the stability of the micelle by the contribution of the weak noncovalent interactions is undesirable.²² In previous reports, acid-sensitive CCM could not only load and deliver drugs more stably but also control and sustain the release of drugs by the breakage of acid-labile cross-linker in the core.^23,24

Folate receptors are overexpressed in most types of epithelium-related cancer cells, while being almost undetectable in healthy tissues or cells.^25,26 Nanocarriers modified by folic acid (FA) can actively deliver drugs to tumors through folate receptor-mediated active targeting,^27,28 resulting in the improved therapeutic effect.²⁶ Meanwhile, the antitumor efficiency may be significantly strengthened by synergetic active and passive tumor targeting.²⁹

Herein, we report a CCM fabricated by the self-assembly of folic acid-polyethylene glycol (FA-PEG) and pyridyldisulfide (PDS),^30,31 with polyethylene glycol (PEG) and FA-PEG as the hydrophilic units and PDS as the cross-linkable and hydrophobic unit, which was sensitive to reducing agents.^32,33 The disulfide bonds in the core of the micelle were formed by thiol-exchange reaction, and the “net structure” consisting of disulfide bonds could protect drugs from leakage into the blood circulation. When the CCM arrived at the tumor sites, the net structure in the core of micelles was destroyed by high concentrations of glutathione (GSH), and the drug loaded by CCM achieved stimuli drug release in response to high reducibility stimulus (Figure 1). In order to explore the unique characteristics of CCM in vitro and in vivo, we used Nile Red and curcumin (Cur) as the model drugs. The drug loading stability and controlled release activities of CCM were investigated in vitro. The cellular uptake and in vitro tumor cell inhibition ability were also studied. The in vivo drug delivery and tumor-targeting profiles were mainly explored by tissue distribution and tumor accumulation experiments.

Figure 1.

Illustration of different behaviors of drug delivering and releasing in vivo between NCM and FA-CCM.

Abbreviations: NCM, noncross-linked micelle; FA, folic acid; CCM, cross-linked micelle; FA-PEG, folic acid-polyethylene glycol; PDS, pyridyldisulfide; Cur, curcumin; DTT, dithiothreitol; GSH, glutathione.

Materials and methods

Materials

N-(3-(Dimethylamino)propyl)-N-ethylcarbodiimide hydrochloride (EDC·HCl), N-hydroxysuccinimide (NHS), dithiothreitol (DTT), and 2,2-azobis (isobutyronitrile) (AIBN) were purchased from Alfa Aesar (Lancashire, UK). mPEG_5k-NH₂ and FA-PEG_5K-NH₂ were purchased from JenKem Technology Co., Ltd. (Beijing, China). 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) and Cur were purchased from Sigma-Aldrich Co. (St Louis, MO, USA). Tetrahydrofuran and dimethyl formamide were provided by Jiangtian Company (Tianjin, People’s Republic of China) and dried by refluxing over calcium hydride and then distilled.

Synthesis and characterizations of polymer and micelles

Chain transfer agent of N-(2-(2-pyridyl disulfide) ethyl methacrylamide (DS) and S-1-dodecyl-S-(α,α′-dimethyl-α″-acetic acid) trithiocarbonate (CTAm) was synthesized as reported.³⁴ Macro chain transfer agent of FA-PEG_5k-CTAm and mPEG_5k-CTAm was synthesized according to our previous work.³⁵ The amphiphilic block copolymers mPEG-b-PDS (PGDS) and FA-PEG-b-PDS (FPGDS) were synthesized by using mPEG_5k-CTAm and FA-PEG_5k-CTAm as the chain transfer agent, respectively. Briefly, mPEG_5k-CTAm (1.073 g, 0.2 mM), DS (3.048 g, 12 mM), and AIBN (6.56 mg, 0.04 mM) were dissolved in anhydrous dimethyl formamide (5 mL) in a 25 mL Schlenk flask. After degassing via three freeze–pump–thaw cycles, the flask was placed in a thermostatic oil bath at 70°C for 24 hours in atmosphere. Then, the solution was dialyzed against pure water for 2 days and finally lyophilized to obtain the powder of PGDS. The polymer FPGDS was synthesized via the same route. The structures and compositions of copolymers were characterized by ¹H NMR (solvent: CDCl₃) using a Varian INOVA 500 MHz NMR instrument at 25°C.

Preparation and characterization of micelles

PGDS micelle (NCM) was prepared via nanoprecipitation method. Briefly, 20 mg of PGDS copolymer was dissolved in 1 mL of dimethyl sulfoxide, and then the mixture was incubated for 20 minutes and dialyzed against phosphate-buffered saline (PBS; 0.01 M, pH 7.4) for 24 hours using a dialysis bag (molecular weight cutoff [MWCO]: 3,500 Da). Finally, the concentration of PGDS polymer in the NCM solution was adjusted to 1 mg/mL for the following experiments. To obtain the disulfide-responsive core cross-linked PGDS micelle (CCM), calculated amount of DTT (1.2 equiv of DS monomers) was added into the prepared NCM and then incubated for 24 hours, which ensured that all of the PDS units in the NCM were cross-linked. Core cross-linked FPGDS micelle (FA-CCM) was prepared through the same route. Particle size and size distribution of these micelles were determined by dynamic light scattering (Brookhaven BI-200SM) at λ=532 nm with a fixed detector angle of 173°. Morphology of the self-assembled structure was investigated using a Hitachi H600 transmission electron microscope at operated voltage of 75 kV.

Characterization of redox sensitivity of CCM

Redox sensitivity of CCM was investigated using varian fluorescence spectrophotometer (Varian, Palo Alto, USA). Here, we chose Nile Red as fluorescent probe. Nile Red-loaded NCM (NCM-NR) and CCM (CCM-NR) were prepared, respectively. Briefly, the polymer (20 mg) was dissolved in dimethyl sulfoxide (1 mL) consisting of Nile Red (20 μg), and then the mixture was dialyzed (MWCO: 3,500 Da) against PBS (0.01 M, pH 7.4), in which DTT (1.2 equiv of DS monomers) was added to prepare the Nile Red-loaded NCM. After incubated for 24 hours, CCM-NR was obtained. NCM-NR and CCM-NR were divided into six groups, which were processed under different conditions such as various pH values and with or without GSH treated. As incubated time went by, the fluorescence values of the treated micelles solution were measured by varian fluorescence spectrophotometer.

Release of Cur in vitro

The release character of Cur from NCM-Cur and CCM-Cur was assessed by the dialysis bag methods. To obtain the drug release profile, Cur was loaded by NCM during NCM synthesis, and CCM-Cur was prepared via similar method of CCM as depicted in the method of synthesis and characterizations of polymer and micelles. Meanwhile, the FA-CCM-Cur was prepared for further studies. Briefly, 50% of PGDS and 50% of FPGDS were co-self-assembled into NCM, DTT (1.2 equiv of DS monomers) was added into the prepared NCM and then incubated for 24 hours, which ensured that all of the PDS units in the PGDS and FPGDS were cross-linked. Drug loading content (DLC) and drug loading efficiency (DLE) were calculated with the following equations:

$$\text{DLC}(\%)=\frac{\text{Weight of loaded Cur}}{\text{Weight of Cur loaded NPs}}\times 100\%$$ (1)

$$\text{DLE}(\%)=\frac{\text{Weihgt of loaded Cur}}{\text{Weight of Cur in feed}}\times 100\%$$ (2)

NCM-Cur (5 mL, 1.0 mg/mL) and CCM-Cur (5 mL, 1.0 mg/mL) were sealed in a dialysis bag (MWCO: 8,000 Da) and incubated in 25 mL different kinds of buffer solutions (pH 7.4 or 5.0 value, and with or without GSH treated) at 37°C under stirring at a speed of 80 rpm. 5 mL of buffer solutions was taken out and supplemented by the same volume of fresh buffer solutions at selected time intervals. The concentration of Cur in removed buffer solutions was measured by ultraviolet–visible spectrophotometry at 425 nm, and the percentages of Cur released from micelles were plotted against time. Each sample for the release kinetics study was conducted in triplicate.

Cellular uptake study

HeLa cells (human henrietta lackes strain of cancer cell line) were cultured in Dulbecco’s Modified Eagle’s Medium supplemented with 10% fetal bovine serum at 37°C in 5% CO₂. All cell experiments were carried out according to the People’s Republic of China national standard (GB/T 16886.5-2003) and were approved by the Chinese Academy of Medical Science and Peking Union Medical College. Cells were seeded into a 12-well plate with a density of 10⁵ cells/well. After incubation for 24 hours, cells were incubated with free Cur, NCM-Cur, CCM-Cur, and FA-CCM-Cur at equivalent Cur concentration of 20 μg/mL, respectively. After cultured for 8 hours, the mixture of liquids in each well was discarded and washed three times with PBS. Each well was observed using fluorescence microscopy with an excitation wavelength of 490 nm.

For flow cytometric analyses, HeLa cells were seeded onto 24-well plate with a density of 10⁵ cells/well and then cultured in 5% CO₂ atmosphere at 37°C. After 24 hours of incubation, culture medium was replaced and cultured with various Cur formulations at Cur concentration of 20 μg/mL, respectively. Cells incubated with PBS were used as blank control. Cells in new medium were incubated for 8 hours in 5% CO₂ atmosphere at 37°C, after washing three times with cold PBS, cells were harvested for quantitative analysis by flow cytometer on a FACS calibur (BD Bioscience, New Jersey, USA).

MTT assay

HeLa cells were placed into 96-well plates with a density of 5×10³ per well. After cultured in Dulbecco’s Modified Eagle’s Medium supplemented with 10% fetal bovine serum at 37°C in 5% CO₂ for 24 hours, a series concentration of empty micelles (including NCM, CCM, and FA-CCM) and various formulations of Cur (free Cur, NCM-Cur, CCM-Cur, and FA-CCM-Cur) with different dilutions were added to the corresponding plate and incubated for 24 hours. Medium in each well was replaced by 20 μL of MTT solution and further incubated for 4 hours. The optical density (OD) at 570 nm was detected by a microplate enzyme-linked immunosorbent assay reader. Cells treated with PBS were used as control, and cell viability was expressed by ([OD_treat − OD_blank]/[OD_control − OD_blank]) ×100. All samples are presented as mean ± standard deviation (SD) (n=6).

Tissue distribution and tumor accumulations in vivo

BALB/c nude mice were purchased from Vital River Laboratory Animal Technology Co., Ltd. (Beijing, People’s Republic of China). The subcutaneous xenograft model of cervical cancer was established by subcutaneously injecting 10⁶ HeLa cells in a 0.2 mL of PBS into the right flank of nude mice. The BALB/c nude mice bearing HeLa tumor model were acclimated at 25°C and 55% of humidity under natural light/dark conditions before the size of tumor satisfied the experimental requirements, and all animal experiments were carried out according to the People’s Republic of China national standard (GB/T 16886.6-1997). All animal experiments were approved by the Chinese Academy of Medical Science and Peking Union Medical College.

When the volume of tumor model reached 200 mm³, nude mice were divided into four groups, including free Cur, NCM-Cur, CCM-Cur, and FA-CCM-Cur group, and they were injected intravenously via tail vein at equivalent Cur dose of 10 mg/kg body weight. The tumor and major organs (heart, liver, spleen, lung, and kidney) were dissected from sacrificed mice at scheduled time (1 hour, 6 hours, 24 hours, and 48 hours), these obtained tissues were examined using Kodak IS in vivo imaging system through the fluorescence of Cur with an excitation wavelength of 465 nm and an emission wavelength of 535 nm.

Statistical analysis

One-way analysis of variance was used for the statistical analysis. *P<0.05 and **P<0.01 were utilized for statistical significance. All data were shown as mean ± SD.

Results and discussion

Synthesis and characterization of copolymer

The PGDS copolymers were synthesized via reversible addition fragmentation chain transfer polymerization,³⁵ the synthesis routes are shown in Figure 2A. Chemical structures and compositions of PGDS were determined by ¹H NMR. As shown in Figure 3A, the monomer DS had been successfully synthesized. All typical peaks of PEG and DS are shown in Figure 3B. The characteristic peaks of DS appeared at 7.02 ppm (c), 8.12 ppm (d), and 7.65 ppm (a+b), and a library of new signals attributed to the protons of PEG chains was found to be at 3.64 ppm (g+h). The copolymers consisted of 31 DS monomers, which were calculated by ¹H NMR. Overall, PGDS copolymers were successfully synthesized.

Figure 2.

The synthesis route schematic representation of the CCM and FA-CCM-Cur.

Notes: The synthesis route and cross-linking of CCM (A). Schematic representation of the preparation and cargos loading method of NCM and FA-CCM (B).

Abbreviations: CCM, cross-linked micelle; NCM, noncross-linked micelle; FA, folic acid; FA-PEG, folic acid-polyethylene glycol; PDS, pyridyldisulfide; Cur, curcumin; DTT, dithiothreitol; AIBN, 2,2-azobis (isobutyronitrile).

Figure 3.

¹H NMR spectrum of DS monomer and PGDS copolymer.

Notes: ¹H NMR spectrum of DS monomer (A) and PGDS copolymer (B) in CDCl₃.

Abbreviations: DS, N-(2-(2-pyridyl disulde) ethyl methacrylamide; PGDS, mPEG-b-PDS.

NCM was prepared via nanoprecipitation method. As shown in Figure 4, the diameter of NCM was ~105.7 nm with a narrow polydispersity index of 0.21. Similarly, the CCM retained a spherical shape and smaller particle size of 91.2 nm with a narrow polydispersity index of 0.23 following a disulfide bond cross-linking.

Figure 4.

Size distribution and morphology of NCM and CCM.

Notes: Size distribution and morphology of NCM (A) and CCM (B) measured by DLS and TEM.

Abbreviations: DLS, dynamic light scattering; TEM, transmission electron microscope; NCM, noncross-linked micelle; CCM, cross-linked micelle.

Characterization of redox sensitivity of CCM

The encapsulation stability of CCM compared with NCM under different pH values was assessed by the change in fluorescence intensity. As shown in Figure 5A–D, unlike the obvious decline of fluorescence intensity of NCM-NR with increased incubation time, there was no significant difference in CCM-NR, which indicated that the drug loading stability of CCM was significantly better than that of NCM. The rate of dye release of NCM-NR incubated in pH 5.0 buffer was faster than that in pH 7.4 buffer. This may be caused by the deprotonation of the pyridine ring in the hydrophobic part at acid condition,^36,37 which led to expansion of the hydrophobic core and accelerated release of Nile Red.³⁸ Moreover, when being treated with 10 mM GSH, fluorescence intensity of CCM-NR significantly decreased and ~80% of Nile Red was released after cultured for 24 hours (Figure 5E and F). These results indicated that this CCM could retain higher drug loading stability and achieve targeted drug release in response to high reducibility stimulus.^32,39

Figure 5.

Nile Red release profiles of NCM and CCM at different pH values and reducing environments within 24 hours.

Notes: The release from NCM at neutral pH (A) and acidic pH (B), the release from CCM at neutral pH (C) and acidic pH (D), and the release from CCM at neutral pH (E) and acidic pH (5.0) (F) under 10 mM GSH.

Abbreviations: NCM, noncross-linked micelle; CCM, cross-linked micelle; GSH, glutathione; h, hours.

Drug release studies in vitro

The NCM-Cur, CCM-Cur, and FA-CCM-Cur were prepared. The DLC and DLE were determined by ultraviolet–visible spectra, and the size distribution of these micelles was evaluated by dynamic light scattering. As shown in Table 1, the DLC and DLE of the three micelles were ~8% and ~80%, respectively. The particle sizes of them were ~100 nm, which could enable these spherical vehicles to target tumor tissues via enhanced permeability and retention effect.^5,6

Table 1.

Chemical characteristics of different Cur-loaded micelles

Sample	Size (nm)	PDI	DLC (%)	DLE (%)
NCM-Cur	103±3.2	0.35±0.33	8.25	82.5
CCM-Cur	100±2.6	0.42±0.30	8.35	83.5
FA-CCM-Cur	108±3.5	0.46±0.42	8.31	83.1

Note: Results are expressed as mean ± SD (n=3).

Abbreviations: PDI, polydispersity index; DLC, drug loading content; DLE, drug loading efficiency; NCM, noncross-linked micelle; Cur, curcumin; CCM, core cross-linked micelle; FA, folic acid.

The Cur release profiles from NCM and CCM are shown in Figure 6A and 6B, less Cur was released from CCM than from NCM at pH 7.4, which proved higher loading stability after being cross-linked by disulfide bond. These results may contribute to the reduced drug leakage from CCM during sample storage and blood circulation in vivo.⁴⁰ Meanwhile, compared to NCM-Cur, CCM-Cur realized sustained release under the condition of 10 mM GSH, ~70%–80% of Cur released within 12 hours of incubation at neutral pH or acidic pH environment (Figure 6A and B). The responsive drug release of CCM-Cur by 10 mM GSH treatment may facilitate the intracellular delivery of loaded molecules and drug accumulation in tumors.^24,31,41 Besides, the different release behaviors of NCM-Cur and CCM-Cur at pH 5.0 was attributed to the pyridine ring of NCM, which would be deprotonated to the acid stimuli and thus accelerated Cur release.

Figure 6.

Cur release profiles of NCM and CCM at different conditions.

Notes: Cur release profiles of NCM (A) and CCM (B) at different pH values with or without GSH treated. Data reported are the mean ± SD for triplicate samples.

Abbreviations: NCM, noncross-linked micelle; CCM, cross-linked micelle; GSH, glutathione; h, hours.

Cellular uptake studies

To investigate the possibility of using these micelles as drug delivery vehicles, cellular uptake studies were performed. As can be seen from Figure 7A, Cur intensity from NCM-Cur was lower than that from CCM-Cur in HeLa cells. This may due to the high encapsulation stability of CCM-Cur in the culture medium, which make more CCM-Cur to be taken up by cells and thus higher fluorescence intensity.^34,42 Moreover, the different release behaviors between NCM-Cur and CCM-Cur, which was endowed by the redox-responsive cross-linkers in the core of CCM-Cur, enabled the CCM-Cur to stably encapsulate and deliver Cur into cells, and then specifically release it in response to the high reducibility in Hela cells.⁴³ From Figure 7A we can also observe that the Cur released from FA-CCM-Cur was stronger than that from CCM-Cur. As we all know FA receptors are overexpressed on the surface of many tumor cells, such as HeLa cells and human squamous cell carcinoma cell line of the oral cavity (KB cell).^44–48 The surface modification of nanocarriers by FA could effectively enhance their binding ability to FA positive cells via the folate receptor-mediated targeting delivery, as evidenced by the highest fluorescence accumulation in HeLa cells of the FA-CCM-Cur group. Furthermore, the flow cytometry was used for quantitative detection of the cellular uptake. As shown in Figure 7B, similar trends were found as the observations in Figure 7A.

Figure 7.

Cellular uptake of different Cur formulations in HeLa cells after incubation for 8 hours.

Notes: (A) Cellular uptake of different Cur formulations in HeLa cells after incubation for 8 hours (blue and green represented the cell nucleus and Cur, respectively). Scale bar =25 μm. (B) Quantitative analysis of cell uptake by HeLa cells treated with free Cur or Cur-loaded micelles after treatment for 8 hours. (*P<0.05, **P<0.01, a = in comparison with free Cur, b = in comparison with NCM-Cur, and c = in comparison with CCM-Cur).

Abbreviations: Cur, curcumin; NCM, noncross-linked micelle; CCM, cross-linked micelle; DAPI, 4′,6-diamidino-2-phenylindole; FA, folic acid.

Cell viability studies

To explore the biocompatibility of the blank micelles and the in vitro antitumor ability of Cur-load micelles, we used the MTT assay to observe the viability of HeLa cells. As shown in Figure 8A, all the micelles exhibited no observable cytotoxicity against HeLa cells even if the concentrations were as high as 5 mg/mL. Meanwhile, the cytotoxicity results of different Cur formulations shown in Figure 8B indicated a dose-dependent pattern after incubation for 24 hours. The cell suppression capacity of free Cur was strongest than other three formulations, this was presumably caused by its easy diffusion through the cellular membrane, compared with the delayed release of Cur from the micelles inside the cells.^49,50 NCM-Cur group showed highest cell viability, which can be explained by insufficient drug diffused out from NCM, resulting in lowest antitumor efficiency.⁵¹ The core cross-linking micelle showed better cell inhibition effect than NCM-Cur, which was mainly attributed to the controlled and sustained release by the responsibility of disulfide to the reducing agents in the cancer cells.^32,33 Furthermore, FA-CCM-Cur enhanced the inhibition of cell proliferation and showed the best antitumor potential in cellular level, which coincided well with the cellular uptake results.

Figure 8.

Cell viability of blank micelles and Cur loaded micelles.

Notes: Cell viability of HeLa cells treated with different concentrations of blank micelles (A) and different concentrations of Cur-loaded micelles (B) after incubation for 24 hours by MTT assay. Values are reported as the mean ± SD (n=6).

Abbreviations: Cur, curcumin; MTT, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide; NCM, noncross-linked micelle; CCM, cross-linked micelle; FA, folic acid.

Ex vivo distribution and tumor accumulations

The distribution and tumor accumulations results of various Cur formulations are shown in Figure 9A and B. Free Cur suffered rapid clearance from main organs and little drug accumulated into tumor after injection for 6 hours. The result verified the fact that there was a short half-life and rapid clearance of Cur.⁵² Meanwhile, the shortest time of tumor accumulation of NCM-Cur among the three micelle groups may weaken the efficacy of cancer chemotherapy, which was mainly caused by drug leakage in blood circulation or slow passive diffusion into tumor site.^12,38 CCM-Cur showed longer residence time in tumor until 24 hours after injection. This may be resulted from the fact that the CCMs remained intact during the circulation,^38,53 and achieved rapid release in response to the GSH stimulus at the tumor sites. Therefore, FA-CCM-Cur, which combined folate receptor-mediated active targeting drug delivery with the stable drug delivery during circulation endowed by the core cross-linking, showed the highest (at all the time points) and the longest (even 48 hours after injection) Cur accumulation in tumor. Meanwhile, we found that a relatively higher accumulation in the liver was observed compared to that in other organs, which is likely due to the nonspecific accumulation or clearance of nanoparticles by the reticuloendothelial system. Meanwhile, FA-CCM was also dissolved in liver, which was caused by high GSH concentrations in liver. The statistical results of Cur accumulated livers in the three micelles showed no significant differences (Figure 9C).

Figure 9.

Tissue distribution and tumor accumulations of different Cur formulations.

Notes: Tissue distribution and tumor accumulation images of different Cur formulations (A) (from left to right is the heart, liver, spleen, lung, kidney, and tumor, respectively). Quantitative measurement of the Cur intensity in tumor (B) and in liver (C) within 48 hours (*P<0.05, **P<0.01, a = in comparison with free Cur, b = in comparison with NCM-Cur, c = in comparison with CCM-Cur) (values are reported as the mean ± SD, n=3).

Abbreviations: Cur, curcumin; MTT, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide; NCM, noncross-linked micelle; CCM, cross-linked micelle; FA, folic acid; h, hours.

Conclusion

In summary, we have demonstrated a self-assembled and CCM based on PEG-PDS/FA-PEG-PDS copolymers. With nanosized spherical shapes, CCM/FA-CCM can be used as a safe drug carrier; it showed enhanced drug encapsulation ability and sensitivity of drug release to GSH stimuli. Aided by the FA ligand, FA-CCM-Cur displayed good tumor cell inhibition ability in vitro and stable drug delivery during circulation, and most importantly, it showed high and durable drug accumulation in a tumor. These results suggested that FA-CCM may be a promising vehicle for stable and intelligent tumor drug delivery. Further studies will focus on the in vivo antitumor efficiency and the optimization of the drug dose to obtain the most effective dose with less side effects during the treatment.